Middle East & Africa Breaking

WHO Advocates Ervebo Vaccine Trial Amid DR Congo Ebola Outbreak

Fanaar Editorial · Published AUG 10, 2026 · 16:20 UTC · Updated AUG 10, 2026 · 17:35 UTC

UPDATE — Aug 10, 17:35 UTC: The new article reveals that the Ebola outbreak in the Democratic Republic of Congo began months before the official declaration and includes the rare Bundibugyo virus strain. Initial cases were misidentified, leading to delayed response efforts.

The World Health Organization (WHO) has urgently recommended the initiation of a large-scale human trial for Ervebo, the only approved Ebola vaccine. This directive seeks to evaluate the vaccine's potential efficacy in providing cross-protection against the ongoing deadly Ebola outbreak in the Democratic Republic of Congo (DRC).

Amidst rising concerns over the spread of a lethal strain of the Ebola virus in the DRC, the WHO's panel of vaccine experts emphasized the critical need to understand the vaccine's effectiveness against diverse strains. The ongoing epidemic necessitates swift action to bolster immunization strategies and curb viral transmission.

The call for trials underlines the urgency in addressing not just the immediate public health threat, but also the broader implications for future outbreaks. Determining the vaccine's cross-protective capabilities could be pivotal in shaping global response strategies to Ebola and similar zoonotic diseases.